Cargando…

Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease

BACKGROUND: Synaptic dysfunction and degeneration are central to Alzheimer’s disease (AD) and have been found to correlate strongly with cognitive decline. Thus, studying cerebrospinal fluid (CSF) biomarkers reflecting synaptic degeneration, such as the presynaptic protein synaptosomal-associated pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nilsson, Johanna, Ashton, Nicholas J., Benedet, Andrea L., Montoliu-Gaya, Laia, Gobom, Johan, Pascoal, Tharick A., Chamoun, Mira, Portelius, Erik, Jeromin, Andreas, Mendes, Muriel, Zetterberg, Henrik, Rosa-Neto, Pedro, Brinkmalm, Ann, Blennow, Kaj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166380/ https://www.ncbi.nlm.nih.gov/pubmed/35659284 http://dx.doi.org/10.1186/s13195-022-01021-8

Ejemplares similares

Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum
por: Gobom, Johan, et al.
Publicado: (2022)

Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies
por: Montoliu-Gaya, Laia, et al.
Publicado: (2023)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
por: Montoliu-Gaya, Laia, et al.
Publicado: (2021)

Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals
por: Benedet, Andréa L., et al.
Publicado: (2019)

Association of plasma P-tau181 with memory decline in non-demented adults
por: Therriault, Joseph, et al.
Publicado: (2021)

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
por: Ashton, Nicholas J., et al.
Publicado: (2021)

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease
por: Brinkmalm, Ann, et al.
Publicado: (2014)

CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
por: Simrén, Joel, et al.
Publicado: (2022)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer’s disease pathology
por: Ashton, Nicholas J., et al.
Publicado: (2023)

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
por: Bayoumy, Sherif, et al.
Publicado: (2021)

Lumbar and ventricular CSF concentrations of extracellular matrix proteins before and after shunt surgery in idiopathic normal pressure hydrocephalus
por: Minta, Karolina, et al.
Publicado: (2021)

Fluid Biomarkers for Synaptic Dysfunction and Loss
por: Camporesi, Elena, et al.
Publicado: (2020)

Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry
por: Sjödin, Simon, et al.
Publicado: (2016)

P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
por: Lantero‐Rodriguez, Juan, et al.
Publicado: (2021)

Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer’s Disease
por: van den Berg, Emma, et al.
Publicado: (2023)

14-3-3 [Formula: see text] -reported early synaptic injury in Alzheimer’s disease is independently mediated by sTREM2
por: Woo, Marcel S., et al.
Publicado: (2023)

Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals
por: Lussier, Firoza Z, et al.
Publicado: (2021)

The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
por: Kvartsberg, Hlin, et al.
Publicado: (2018)

Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry
por: Camporesi, Elena, et al.
Publicado: (2022)

Biomarker modeling of Alzheimer’s disease using PET-based Braak staging
por: Therriault, Joseph, et al.
Publicado: (2022)

Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s disease
por: Kang, Min Su, et al.
Publicado: (2020)

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease
por: Cicognola, Claudia, et al.
Publicado: (2018)

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Ex vivo(18)O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
por: Portelius, Erik, et al.
Publicado: (2017)

A three‐range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease
por: Brum, Wagner S., et al.
Publicado: (2022)

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
por: Sjödin, Simon, et al.
Publicado: (2017)

Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury
por: Minta, Karolina, et al.
Publicado: (2020)

Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS
por: Hölttä, Mikko, et al.
Publicado: (2012)

Harmonization and standardization of biofluid‐based biomarker measurements for AT(N) classification in Alzheimer's disease
por: Giangrande, Chiara, et al.
Publicado: (2023)

Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase
por: Becker, Bruno, et al.
Publicado: (2018)

Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases
por: Minta, K., et al.
Publicado: (2020)

Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability
por: Simrén, Joel, et al.
Publicado: (2022)

Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment
por: Pascoal, Tharick A., et al.
Publicado: (2020)

Amyloid‐dependent and amyloid‐independent effects of Tau in individuals without dementia
por: Therriault, Joseph, et al.
Publicado: (2021)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans
por: Hölttä, Mikko, et al.
Publicado: (2016)

An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform
por: Li, Danni, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1d5ojmc0fpcdcvqu2q1m7r7urc